Evaluation of tolerability and antibody response after recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) and a single dose of recombinant hepatitis B vaccine

Vaccine

Volumn 14, Issue 13, 1996, Pages 1199-1204

  Tarr, Philip E ^a,b   Lin, Rong ^a   Mueller, Edgar A ^a   Kovarik, John M ^a   Guillaume, Michel ^c   Jones, Thomas C ^d  

^a Sandoz Pharma Ltd   (Switzerland)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c Hopital de la Fondation Cognacq Jay   (France)

^d Clinical Research Consultants   (Switzerland)

Author keywords

Hepatitis B; rhGM CSF; Vaccine adjuvant

Indexed keywords

HEPATITIS B VACCINE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT VACCINE;

ADULT; ANTIBODY RESPONSE; ANTIGEN PRESENTATION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG TOLERABILITY; ERYTHEMA; HEADACHE; HEPATITIS B; HUMAN; HUMAN EXPERIMENT; INTRADERMAL DRUG ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MYALGIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTORS, RECOMBINANT; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMANS; MALE; VACCINES, SYNTHETIC;

EID: 0030250633     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(96)00031-X     Document Type: Article

References (35)

1. 1 Ruef, C. and Coleman, D.L. Granulocyte-macrophage colony-stimulating factor: pleiotropic cytokine with potential clinical usefulness. Rev. Infect. Dis. 1990, 12, 41-62
2. 2 Witmer-Pack, M.D., Olivier, W., Valinsky, J., Schuler, G. and Steinman, R.M. Granulocyte-macrophage colony-stimulating factor is essential for the viability and function of cultured murine epidermal Langerhans cells. J. Exp. Med. 1987, 166, 1484-1498
3. 3 Markowicz, S. and Engleman, E. Granulocyte-macrophage colony-stimulating factor promotes differentiation and survival of human peripheral blood dendritic cells in vitro. J. Clin. Invest. 1990, 85, 955-961
4. 4 Sallusto, F. and Lanzavecchia, A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte-macrophage colony-stimulating factor plus Interleukin-4 and downregulated by tumor necrosis factor-α. J. Exp. Med. 1994, 179, 1109-1118
5. 5 Steinman, R. The dendritic cell system and its role in immunogenicity. A. Rev. Immunol. 1991, 9, 271-296
6. 6 Levin, D., Constant, S., Pasqualini, T., Flavell, R. and Bottomly, K. Role of dendritic cells in the priming of CD4+ T lymphocytes to peptide antigen in vivo. J. Immunol. 1993, 151, 6742-6750
7. 7 Young, J.W. and Steinman, R.M. Dendritic cells stimulate primary human cytolytic lymphocyte responses in the absence of CD4+ helper T cells. J. Exp. Med. 1990, 171, 1315-1322
8. 8 Larsen, C.P., Ritchie, S.C., Hendrix, R. et al. Regulation of immunostimulatory function and costimulatory molecule (B7-1 and B7-2) expression on murine dendritic cells. J. Immunol. 1994, 152, 5208-5219
9. 9 Young, J.W., Koulova, L., Soergel, S.A., Clark, E.A., Steinman, R.M. and Dupont, B. The B7/BB1 antigen provides one of several costimulatory signals for the activation of CD4+ T lymphocytes by human dendritic cells in vitro. J. Clin. Invest. 1992, 90, 229-237
10. 10 Fischer, H.-G., Frosch, S., Reske, K. and Reske-Kunz, A.B. Granulocyte-macrophage colony-stimulating factor activates macrophages derived from bone marrow cultures to synthesis of MHC class II molecules and to augmented antigen presentation function. J. Immunol. 1988, 141, 3882-3888
11. 11 Morrissey, P.J., Bressler, L., Park, L.S., Alpert, A. and Gillis, S. Granulocyte-macrophage colony-stimulating factor augments the primary antibody response by enhancing the function of antigen-presenting cells. J. Immun. 1987, 139, 1113-1119
12. 12 Germain, R.N. MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. Cell 1994, 76, 287-299
13. 13 T.C. Jones, Future uses of granulocyte-macrophage colony-stimulating factor (GM-CSF). In: The Metcalf Forum: Polyfunctionality of Hemato poietic Regulators (Ed. Metcalf, D.). AlphaMed Press, 1994, pp. 1-11
14. 14 Trinchieri, G. Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 1994, 84, 4008-4027
15. 15 Liehl, E., Hildebrandt, J., Lam, C. and Mayer, P. Prediction of the role of granulocyte-macrophage colony-stimulating factor in animals and man from in vitro results. Eur. J. Clin. Microbiol. Infect. Dis. 1994, 13Suppl 2, S9-S17
16. 16 Hibberd, P.L., Rubin, R.H. and Dienstag, J.L. Needs unfulfilled by current hepatitis B vaccines. In: Hepatitis B Vaccines in Clinical Practice (Ed. Ellis R.W.). Marcel Dekker Inc., New York, 1993
17. 17 Hollinger, F.B. and Dreesman, G.R. Immunology of Hepatitis B vaccine. In: Manual of Clinical Laboratory Immunology (Eds Rose, N.R., Freidman, H. and Fahey J.L.). American Society for Microbiology, Washington DC, 1986, pp. 558-572
18. 18 West, D.J. Scope and design of hepatitis B vaccine clinical trials. In: Hepatitis B Vaccines in Clinical Practice (Ed. Ellis, R.W.). Marcel Dekker Inc., New York, 1993, pp. 159-177
19. 19 Kaplan, G., Walsh, G., Guido, L.S. et al. Novel responses of human skin to intradermal recombinant granulocyte-macrophage colony-stimulating factor: Langerhans cell recruitment, Keratinocyte growth and enhanced wound healing. J. Exp. Med. 1992, 175, 1717-1728
20. 20 Reed, E., Jui, J., Daya, M. and Schmidt, T. Intramuscular vs. intradermal hepatitis B vaccination of prehospital care personnel (abstract 666). In: Program and Abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, (New Orleans). American Society for Microbiology, Washington, DC, 1993, p. 241
21. 21 Gonzalez, M.L., Usandizaga, M., Alomar, P. et al. Intradermal and intramuscular route for vaccination against Hepatitis B. Vaccine 1990, 8, 402-405
22. 22 Coleman, P.J., Shaw, F.E. Jr, Serovich, J., Hadler, S.C. and Margolis, H.S. Intradermal hepatitis B vaccination in a large hospital employee population. Vaccine 1991, 9, 723-727
23. 23 Clarke, J.A., Hollinger, F.B., Lewis, E. et al. Intradermal Inoculation with Heptavax-B. J. Am. Med. Assoc. 1989, 262, 2567-2571
24. 24 Tao, M.H. and Levy, R. Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature 1993, 362, 755-758
25. 25 Gupta, R.K., Relyveld, E.H., Lindblad, E.B. et al. Adjuvants - a balance between toxicity and adjuvanticity. Vaccine 1993, 11, 293-306
26. 26 Thoelen, S., Van Damme, P., Meeus, A., Collard, F., Slaoupui, M. and Vandepapeliere, P. Immunogenicity of a recombinant hepatitis B vaccine with monophosphoryl lipid A administered following various two-dose schedules (abstract 340). In: Program and Abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, (New Orleans). American Society for Microbiology, Washington, DC, 1993, p. 182
27. 27 Dranoff, G., Jaffee, E., Lazenby, A. et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl Acad. Sci. USA 1993, 90, 3539-3543
28. 28 De Vries, E.G.E., Willemse, P.H.B., Biemsa, B., Stern, A.C., Limburg, P.C. and Vellenga, E. Flare-up of rheumatoid arthritis during GM-CSF treatment after chemotherapy. Lancet 1991, 338, 517-518
29. 29 Nathan, F.E. and Besa, E.C. GM-CSF and accelerated hemolysis. N. Engl. J. Med. 1992, 326, 417
30. 30 Hansen, P.B., Johnsen, H.E. and Kippe, E. Autoimmune hypothyroidism and granulocyte-macrophage colony-stimulating factor. Eur. J. Haemat. 1993, 50, 183-184
31. 31 Hoekman, K., Von Bloomberg-Van der Flier, B.M.E., Wagstaff, J., Drexhage, H.A. and Pinedo, H.M. Reversible thyroid dysfunction during treatment with GM-CSF. Lancet 1991, 338, 541-542
32. 32 Estey, E.H., Kurzrock, R., Talpaz, M. et al. Effects of low doses of recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with myelodysplastic syndromes. Br. J. Haemat. 1991, 77, 291-295
33. 33 Kurzrock, R., Talpaz, M. and Gutterman, J.U. Very low doses of GM-CSF administered alone or with erythropoietin in aplastic anemia. Am. J. Med. 1992, 93, 41-48
34. 34 Burgess, A.W., Begley, C.G., Johnson, G.R. et al. Purification and properties of bacterially synthesized human granulocyte-macrophage colony-stimulating factor. Blood 1987, 69, 43-51
35. 35 Lanzavecchia, A. Identifying strategies for immune intervention. Science 1993, 260, 937-944